Skip navigation
Skip navigation

Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease

Subramaniam, Kavitha; Fallon, Kieran; Ruut, Tom; Lane, D; McKay, R.; Shadbolt, Bruce; Ang, S.; Cook, Matthew; Platten, J.; Pavli, Paul; Taupin, Douglas


Background Muscle wasting or sarcopenia arising from chronic inflammation is found in 60% of patients with Crohn's disease. Transcriptional protein NF-κB reduces muscle formation through MyoD transcription and increases muscle breakdown by proteolysis. Aim As TNF is a potent activator of NF-κB, and anti-TNF agent infliximab (IFX) prevents NF-κB activation, to determine whether or not Crohn's patients treated with IFX gain muscle volume and strength. Methods We performed a...[Show more]

CollectionsANU Research Publications
Date published: 2015
Type: Journal article
Source: Alimentary pharmacology & therapeutics
DOI: 10.1111/apt.13058


File Description SizeFormat Image
01_Subramaniam_Infliximab_reverses_2015.pdf482.77 kBAdobe PDF    Request a copy

Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator